Related Experiment Video
Updated: May 17, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Review: systemic inflammation and Alzheimer's disease
1University of Southampton, Division of Clinical and Experimental Science, Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK. ch4@soton.ac.uk
Neuropathology and Applied Neurobiology
|October 11, 2012
Summary
Systemic inflammation plays a key role in Alzheimer's disease (AD) pathogenesis, potentially predating amyloid deposition. Further research is needed to understand systemic inflammation's impact on AD and its links to central nervous system inflammation.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Emerging evidence suggests systemic inflammation is crucial in Alzheimer's disease (AD) development.
- The role of inflammation in AD is often viewed as a contributor, but may precede amyloid plaque formation.
- Current therapies targeting central inflammation in AD and mild cognitive impairment have yielded disappointing results.
Purpose of the Study:
- To investigate the role of systemic inflammation in Alzheimer's disease pathogenesis.
- To explore how systemic inflammation affects the development and progression of Alzheimer's disease.
- To understand the communication pathways between systemic and central innate immune systems in Alzheimer's disease.
Main Methods:
- Review of existing evidence on systemic inflammation and Alzheimer's disease.
- Analysis of the impact of systemic inflammation on neurodegenerative processes.
- Exploration of the interplay between peripheral and central immune responses.
Main Results:
- Systemic inflammation is increasingly recognized as a significant factor in Alzheimer's disease.
- The influence of systemic inflammation may occur earlier in the disease process than previously thought, potentially before amyloid pathology.
- Existing therapeutic strategies have overlooked the importance of modulating systemic inflammation.
Conclusions:
- A deeper understanding of systemic inflammation's effects on Alzheimer's disease is essential for developing novel therapeutic approaches.
- Targeting systemic inflammation, alongside central inflammation, may offer a more effective strategy for managing Alzheimer's disease.
- Investigating the communication between systemic and central innate immunity is critical for future Alzheimer's research.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...